| Year |
Citation |
Score |
| 2022 |
Cvrljevic AN, Butt U, Huhtinen K, Grönroos TJ, Böckelman C, Lassus H, Bützow R, Haglund C, Kaipio K, Arsiola T, Laajala TD, Connolly DC, Ristimäki A, Carpén O, Pouwels J, et al. Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype. Molecular Cancer Therapeutics. PMID 35364610 DOI: 10.1158/1535-7163.MCT-21-0622 |
0.305 |
|
| 2020 |
Lähde M, Heino S, Högström J, Kaijalainen S, Anisimov A, Flanagan D, Kallio P, Leppänen VM, Ristimäki A, Ritvos O, Wu K, Tammela T, Hodder M, Sansom OJ, Alitalo K. Expression of R-spondin1 in Apc Mice Reduces Growth of Intestinal Adenomas by Altering Wnt and TGFB Signaling. Gastroenterology. PMID 32941878 DOI: 10.1053/J.Gastro.2020.09.011 |
0.348 |
|
| 2020 |
Holm M, Nummela P, Heiskanen A, Satomaa T, Kaprio T, Mustonen H, Ristimäki A, Haglund C. N-glycomic profiling of colorectal cancer according to tumor stage and location. Plos One. 15: e0234989. PMID 32598367 DOI: 10.1371/Journal.Pone.0234989 |
0.324 |
|
| 2020 |
Holm M, Joenväärä S, Saraswat M, Tohmola T, Ristimäki A, Renkonen R, Haglund C. Plasma protein expression differs between colorectal cancer patients depending on primary tumor location. Cancer Medicine. PMID 32452655 DOI: 10.1002/Cam4.3178 |
0.366 |
|
| 2020 |
Holm M, Joenväärä S, Saraswat M, Tohmola T, Ristimäki A, Renkonen R, Haglund C. Preoperative Radiotherapy Leads to Significant Differences in the Plasma Protein Profile of Rectal Cancer Patients. Oncology. 1-8. PMID 32294655 DOI: 10.1159/000505697 |
0.342 |
|
| 2020 |
Osterlund E, Isoniemi H, Kytölä S, Kononen J, Pfeiffer P, Soveri L, Keinänen M, Sorbye H, Nunes L, Salminen T, Nieminen L, Halonen P, Ålgars A, Sundström J, Kallio R, et al. SO-22 Atypical non-V600E BRAF (aBRAF) mutations as a prognostic and predictive factor in real-life metastatic colorectal cancer patients from the Nordic countries Annals of Oncology. 31. DOI: 10.1016/J.Annonc.2020.04.037 |
0.322 |
|
| 2019 |
Lasota J, Chłopek M, Lamoureux J, Christiansen J, Kowalik A, Wasąg B, Felisiak-Gołąbek A, Agaimy A, Biernat W, Canzonieri V, Centonze G, Chmielik E, Daum O, Dubová M, Dziuba I, et al. Colonic Adenocarcinomas Harboring NTRK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 16 Cases and Review of the Literature. The American Journal of Surgical Pathology. PMID 31567189 DOI: 10.1097/Pas.0000000000001377 |
0.377 |
|
| 2019 |
Cajuso T, Sulo P, Tanskanen T, Katainen R, Taira A, Hänninen UA, Kondelin J, Forsström L, Välimäki N, Aavikko M, Kaasinen E, Ristimäki A, Koskensalo S, Lepistö A, Renkonen-Sinisalo L, et al. Retrotransposon insertions can initiate colorectal cancer and are associated with poor survival. Nature Communications. 10: 4022. PMID 31492840 DOI: 10.1038/S41467-019-11770-0 |
0.378 |
|
| 2019 |
Chakroborty D, Emani MR, Klén R, Böckelman C, Hagström J, Haglund C, Ristimäki A, Lahesmaa R, Elo LL. L1TD1 - a prognostic marker for colon cancer. Bmc Cancer. 19: 727. PMID 31337362 DOI: 10.1186/S12885-019-5952-2 |
0.344 |
|
| 2019 |
Kelppe J, Thorén H, Ristimäki A, Haglund C, Sorsa T, Hagström J. BRAF V600E expression in ameloblastomas - a 36 patient cohort from Helsinki University Hospital. Oral Diseases. PMID 30811720 DOI: 10.1111/Odi.13072 |
0.328 |
|
| 2019 |
Kauppila JH, Ohtonen P, Karttunen TJ, Kokkola A, Laine S, Rantanen T, Ristimäki A, Räsänen JV, Saarnio J, Sihvo E, Toikkanen V, Tyrväinen T. Finnish National Esophago-Gastric Cancer Cohort (FINEGO) for studying outcomes after oesophageal and gastric cancer surgery: a protocol for a retrospective, population-based, nationwide cohort study in Finland. Bmj Open. 9: e024094. PMID 30782726 DOI: 10.1136/Bmjopen-2018-024094 |
0.307 |
|
| 2018 |
Mäki-Nevala S, Valo S, Ristimäki A, Sarhadi V, Knuutila S, Nyström M, Renkonen-Sinisalo L, Lepistö A, Mecklin JP, Peltomäki P. DNA methylation changes and somatic mutations as tumorigenic events in Lynch syndrome-associated adenomas retaining mismatch repair protein expression. Ebiomedicine. PMID 30578081 DOI: 10.1016/J.Ebiom.2018.12.018 |
0.32 |
|
| 2018 |
Palin K, Pitkänen E, Turunen M, Sahu B, Pihlajamaa P, Kivioja T, Kaasinen E, Välimäki N, Hänninen UA, Cajuso T, Aavikko M, Tuupanen S, Kilpivaara O, van den Berg L, Kondelin J, et al. Contribution of allelic imbalance to colorectal cancer. Nature Communications. 9: 3664. PMID 30202008 DOI: 10.1038/S41467-018-06132-1 |
0.356 |
|
| 2018 |
Saarinen L, Nummela P, Leinonen H, Heiskanen A, Thiel A, Haglund C, Lepistö A, Satomaa T, Hautaniemi S, Ristimäki A. Glycomic Profiling Highlights Increased Fucosylation in Pseudomyxoma Peritonei. Molecular & Cellular Proteomics : McP. PMID 30072579 DOI: 10.1074/Mcp.Ra118.000615 |
0.378 |
|
| 2018 |
Holm M, Saraswat M, Joenväärä S, Ristimäki A, Haglund C, Renkonen R. Colorectal cancer patients with different C-reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics. Plos One. 13: e0195354. PMID 29630649 DOI: 10.1371/Journal.Pone.0195354 |
0.348 |
|
| 2018 |
Hänninen UA, Katainen R, Tanskanen T, Plaketti RM, Laine R, Hamberg J, Ristimäki A, Pukkala E, Taipale M, Mecklin JP, Forsström LM, Pitkänen E, Palin K, Välimäki N, Mäkinen N, et al. Exome-wide somatic mutation characterization of small bowel adenocarcinoma. Plos Genetics. 14: e1007200. PMID 29522538 DOI: 10.1371/Journal.Pgen.1007200 |
0.339 |
|
| 2018 |
Hänninen UA, Katainen R, Tanskanen T, Hamberg J, Ristimäki A, Pukkala E, Taipale M, Mecklin J, Aavikko M, Forsström LM, Pitkänen E, Mäkinen N, Aaltonen LA. Abstract LB-382: Identification of predisposing genes for small bowel adenocarcinoma by exome sequencing Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-382 |
0.373 |
|
| 2018 |
Mäki-Nevala S, Valo S, Ristimäki A, Renkonen-Sinisalo L, Lepistö A, Mecklin J, Peltomäki P. Abstract 3081: Methylation changes and somatic mutations as early events in Lynch syndrome-associated colorectal cancer Cancer Research. 78: 3081-3081. DOI: 10.1158/1538-7445.Am2018-3081 |
0.378 |
|
| 2017 |
Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, El Zimaity H, Fléjou JF, Hansen TP, Hartmann A, Kakar S, Langner C, Nagtegaal I, Puppa G, Riddell R, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 28548122 DOI: 10.1038/Modpathol.2017.46 |
0.364 |
|
| 2017 |
Saarinen L, Nummela P, Thiel A, Lehtonen R, Järvinen P, Järvinen H, Aaltonen LA, Lepistö A, Hautaniemi S, Ristimäki A. Multiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei. Plos One. 12: e0174898. PMID 28426742 DOI: 10.1371/Journal.Pone.0174898 |
0.306 |
|
| 2017 |
Peltola KJ, Penttilä P, Rautiola J, Joensuu H, Hänninen E, Ristimäki A, Bono P. Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer. PMID 28237182 DOI: 10.1016/J.Clgc.2017.01.021 |
0.33 |
|
| 2016 |
Ålgars A, Sundström J, Lintunen M, Jokilehto T, Kytölä S, Kaare M, Vainionpää R, Orpana A, Österlund P, Ristimäki A, Carpen O, Ristamäki R. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer. International Journal of Cancer. PMID 27879995 DOI: 10.1002/Ijc.30507 |
0.309 |
|
| 2016 |
Leijon H, Salmenkivi K, Heiskanen I, Hagström J, Louhimo J, Heikkilä P, Ristimäki A, Paavonen T, Metso S, Mäenpää H, Haglund C, Arola J. HuR in pheochromocytomas and paragangliomas - overexpression in verified malignant tumors. Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. PMID 27357268 DOI: 10.1111/Apm.12571 |
0.403 |
|
| 2016 |
Rautiola J, Lampinen A, Mirtti T, Ristimäki A, Joensuu H, Bono P, Saharinen P. Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma. Plos One. 11: e0153745. PMID 27100185 DOI: 10.1371/Journal.Pone.0153745 |
0.394 |
|
| 2016 |
Nummela P, Leinonen H, Järvinen P, Thiel A, Järvinen H, Lepistö A, Ristimäki A. Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei. Human Pathology. PMID 27038681 DOI: 10.1016/J.Humpath.2016.02.022 |
0.326 |
|
| 2016 |
Ranki T, Pesonen S, Hemminki A, Partanen K, Kairemo K, Alanko T, Lundin J, Linder N, Turkki R, Ristimäki A, Jäger E, Karbach J, Wahle C, Kankainen M, Backman C, et al. Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. Journal For Immunotherapy of Cancer. 4: 17. PMID 26981247 DOI: 10.1186/S40425-016-0121-5 |
0.304 |
|
| 2016 |
Carpen O, Algars A, Sundstrom J, Kytola S, Osterlund P, Lintunen M, Jokilehto T, Kaare M, Orpana A, Vainionpaa R, Ristimaki A, Ristamaki R. EGFR gene copy number to predict response to anti-EGFR treatment and survival in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E15108 |
0.3 |
|
| 2015 |
Taipale K, Liikanen I, Juhila J, Turkki R, Tähtinen S, Kankainen M, Vassilev L, Ristimäki A, Koski A, Kanerva A, Diaconu I, Cerullo V, Vähä-Koskela M, Oksanen M, Linder N, et al. Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26310629 DOI: 10.1038/Mt.2015.143 |
0.369 |
|
| 2015 |
Valo S, Kaur S, Ristimäki A, Renkonen-Sinisalo L, Järvinen H, Mecklin JP, Nyström M, Peltomäki P. DNA hypermethylation appears early and shows increased frequency with dysplasia in Lynch syndrome-associated colorectal adenomas and carcinomas. Clinical Epigenetics. 7: 71. PMID 26203307 DOI: 10.1186/S13148-015-0102-4 |
0.345 |
|
| 2015 |
Vassilev L, Ranki T, Joensuu T, Jäger E, Karbach J, Wahle C, Partanen K, Kairemo K, Alanko T, Turkki R, Linder N, Lundin J, Ristimäki A, Kankainen M, Hemminki A, et al. Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8(+) T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. Oncoimmunology. 4: e1017702. PMID 26140248 DOI: 10.1080/2162402X.2015.1017702 |
0.364 |
|
| 2015 |
Hemminki O, Parviainen S, Juhila J, Turkki R, Linder N, Lundin J, Kankainen M, Ristimäki A, Koski A, Liikanen I, Oksanen M, Nettelbeck DM, Kairemo K, Partanen K, Joensuu T, et al. Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy. Oncotarget. 6: 4467-81. PMID 25714011 DOI: 10.18632/Oncotarget.2901 |
0.38 |
|
| 2015 |
Thiel A, Ristimäki A. Targeted therapy in gastric cancer. Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. 123: 365-72. PMID 25706252 DOI: 10.1111/Apm.12359 |
0.339 |
|
| 2015 |
Donner I, Kiviluoto T, Ristimäki A, Aaltonen LA, Vahteristo P. Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer. Familial Cancer. 14: 241-6. PMID 25576241 DOI: 10.1007/S10689-015-9778-Z |
0.344 |
|
| 2015 |
Nummela P, Saarinen L, Thiel A, Järvinen P, Lehtonen R, Lepistö A, Järvinen H, Aaltonen LA, Hautaniemi S, Ristimäki A. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry. International Journal of Cancer. Journal International Du Cancer. 136: E282-9. PMID 25274248 DOI: 10.1002/Ijc.29245 |
0.368 |
|
| 2015 |
Rautiola J, Lampinen A, Ristimäki A, Mirtti T, Joensuu H, Bono P, Saharinen P. Correlation of endothelial angiopoietin-2 expression with tumor angiogenesis and response to sunitinib in metastatic renal cell carcinoma. Journal of Clinical Oncology. 33: 461-461. DOI: 10.1200/Jco.2015.33.7_Suppl.461 |
0.367 |
|
| 2015 |
Pesonen SA, Ranki T, Jäger E, Karbach J, Wahle C, Joensuu TK, Alanko T, Partanen K, Kairemo K, Turkki R, Linder N, Lundin J, Ristimäki A, Majumder M, Kumar A, et al. An evaluation of local and systemic immune markers following intratumoral administration of a chimeric adenovirus Ad5/3-D24-GMCSF in refractory cancer patients with solid tumors. Journal of Clinical Oncology. 33: 3085-3085. DOI: 10.1200/Jco.2015.33.15_Suppl.3085 |
0.355 |
|
| 2015 |
Pesonen S, Lundin J, Linder N, Turkki R, Ristimäki A, Joensuu T, Kairemo K, Partanen K, Alanko T, Jäger E, Karbach J, Wahle C, Hemminki A, Backman C, Euler Mv, et al. Local immunotherapy with ONCOS-102 shapes harmful tumor associated CD68+ macrophages to become beneficial cells that correlate with increased overall survival Journal For Immunotherapy of Cancer. 3: 1-2. DOI: 10.1186/2051-1426-3-S2-O16 |
0.339 |
|
| 2015 |
Valo S, Kaur S, Ristimäki A, Renkonen-Sinisalo L, Järvinen H, Mecklin J, Nyström M, Peltomäki P. Abstract 4766: DNA methylation changes in Lynch syndrome associated colorectal adenomas and carcinomas Cancer Research. 75: 4766-4766. DOI: 10.1158/1538-7445.Am2015-4766 |
0.365 |
|
| 2015 |
Lampinen A, Rautiola J, Mirtti T, Ristimäki A, Joensuu H, Bono P, Saharinen P. Abstract 4301: Endothelial angiopoietin-2 expression correlates with tumor angiogenesis and response to sunitinib in metastatic renal cell carcinoma Cancer Research. 75: 4301-4301. DOI: 10.1158/1538-7445.Am2015-4301 |
0.4 |
|
| 2015 |
Aavikko M, Kaasinen E, Donner I, Lehti K, Gucciardo E, Shrestha B, Mecklin J, Johannes J, Landerholm K, Pukkala E, Schalin-Jäntti C, Ristimäki A, Vahteristo P, Aaltonen LA. Abstract 2744: Familial multiple metastatic small intestine neuroendocrine tumors: searching for genetic susceptibility Cancer Research. 75: 2744-2744. DOI: 10.1158/1538-7445.Am2015-2744 |
0.329 |
|
| 2014 |
Ranki T, Joensuu T, Jäger E, Karbach J, Wahle C, Kairemo K, Alanko T, Partanen K, Turkki R, Linder N, Lundin J, Ristimäki A, Kankainen M, Hemminki A, Backman C, et al. Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8(+) T-cell response, prominent infiltration of CD8(+) lymphocytes and Th1 type polarization. Oncoimmunology. 3: e958937. PMID 25941579 DOI: 10.4161/21624011.2014.958937 |
0.343 |
|
| 2014 |
Ålgars A, Avoranta T, Österlund P, Lintunen M, Sundström J, Jokilehto T, Ristimäki A, Ristamäki R, Carpén O. Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy. Plos One. 9: e99590. PMID 24940619 DOI: 10.1371/Journal.Pone.0099590 |
0.318 |
|
| 2014 |
Sajanti S, Sirniö P, Väyrynen JP, Tuomisto A, Klintrup K, Mäkelä J, Ristimäki A, Mäkinen MJ. VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma. Virchows Archiv : An International Journal of Pathology. 464: 637-43. PMID 24722974 DOI: 10.1007/S00428-014-1555-0 |
0.306 |
|
| 2014 |
Kurppa KJ, Catón J, Morgan PR, Ristimäki A, Ruhin B, Kellokoski J, Elenius K, Heikinheimo K. High frequency of BRAF V600E mutations in ameloblastoma. The Journal of Pathology. 232: 492-8. PMID 24374844 DOI: 10.1002/Path.4317 |
0.3 |
|
| 2014 |
Valo S, Kaur S, Ristimäki A, Renkonen-Sinisalo L, Järvinen H, Mecklin J, Nyström M, Peltomäki P. Abstract 417: DNA methylation changes in Lynch syndrome and FAP-associated colorectal tumorigenesis Cancer Research. 74: 417-417. DOI: 10.1158/1538-7445.Am2014-417 |
0.348 |
|
| 2014 |
Peltola KJ, Rautiola J, Joensuu H, Hänninen E, Ristimäki A, Bono P. 822Pcorrelation Of Tumour C-Met Expression And Outcome In Patients With Renal Cell Carcinoma (Rcc) Treated With Sunitinib Annals of Oncology. 25. DOI: 10.1093/Annonc/Mdu337.15 |
0.345 |
|
| 2013 |
Thiel A, Ristimäki A. Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. Frontiers in Oncology. 3: 281. PMID 24298448 DOI: 10.3389/Fonc.2013.00281 |
0.36 |
|
| 2013 |
Khanna A, Kauko O, Böckelman C, Laine A, Schreck I, Partanen JI, Szwajda A, Bormann S, Bilgen T, Helenius M, Pokharel YR, Pimanda J, Russel MR, Haglund C, Cole KA, et al. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. Cancer Research. 73: 6757-69. PMID 24072747 DOI: 10.1158/0008-5472.Can-13-1002 |
0.4 |
|
| 2013 |
Thiel A, Heinonen M, Kantonen J, Gylling A, Lahtinen L, Korhonen M, Kytölä S, Mecklin JP, Orpana A, Peltomäki P, Ristimäki A. BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Archiv : An International Journal of Pathology. 463: 613-21. PMID 23963522 DOI: 10.1007/S00428-013-1470-9 |
0.329 |
|
| 2013 |
Lilja L, Haapasaari KM, Bloigu R, Salonen T, Ristimäki A, Turpeenniemi-Hujanen T, Kuittinen O. Increased expression of CIP2A in aggressive subtypes of B-cell lymphoma. Histopathology. 63: 438-9. PMID 23802697 DOI: 10.1111/His.12162 |
0.306 |
|
| 2013 |
Gylfe AE, Kondelin J, Turunen M, Ristolainen H, Katainen R, Pitkänen E, Kaasinen E, Rantanen V, Tanskanen T, Varjosalo M, Lehtonen H, Palin K, Taipale M, Taipale J, Renkonen-Sinisalo L, et al. Identification of candidate oncogenes in human colorectal cancers with microsatellite instability. Gastroenterology. 145: 540-3.e22. PMID 23684749 DOI: 10.1053/J.Gastro.2013.05.015 |
0.384 |
|
| 2013 |
Serlo JA, Helenius IJ, Sampo M, Vettenranta K, Saarinen-Pihkala UM, Kivivuori SM, Riikonen P, Kivioja A, Böhling T, Kallajoki M, Ristimäki A, Vasama K, Tarkkanen M. Ewing's sarcoma family of tumors in Finland during 1990-2009: a population-based study. Acta Oncologica (Stockholm, Sweden). 52: 767-75. PMID 23173760 DOI: 10.3109/0284186X.2012.728714 |
0.331 |
|
| 2013 |
Gylfe AE, Kondelin J, Turunen M, Ristolainen H, Katainen R, Pitkänen E, Kaasinen E, Rantanen V, Tanskanen T, Lehtonen HJ, Palin K, Taipale M, Taipale J, Renkonen-Sinisalo L, Järvinen H, et al. Abstract 3156: New candidate oncogenes discovered in microsatellite unstable colorectal cancer. Cancer Research. 73: 3156-3156. DOI: 10.1158/1538-7445.Am2013-3156 |
0.349 |
|
| 2012 |
Böckelman C, Koskensalo S, Hagström J, Lundin M, Ristimäki A, Haglund C. CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biology & Therapy. 13: 289-95. PMID 22310977 DOI: 10.4161/Cbt.18922 |
0.414 |
|
| 2012 |
Lavilla-Alonso S, Bauer MM, Abo-Ramadan U, Ristimäki A, Halavaara J, Desmond RA, Wang D, Escutenaire S, Ahtiainen L, Saksela K, Tatlisumak T, Hemminki A, Pesonen S. Macrophage metalloelastase (MME) as adjuvant for intra-tumoral injection of oncolytic adenovirus and its influence on metastases development. Cancer Gene Therapy. 19: 126-34. PMID 22095385 DOI: 10.1038/Cgt.2011.76 |
0.371 |
|
| 2012 |
Alhopuro P, Sammalkorpi H, Niittymäki I, Biström M, Raitila A, Saharinen J, Nousiainen K, Lehtonen HJ, Heliövaara E, Puhakka J, Tuupanen S, Sousa S, Seruca R, Ferreira AM, Hofstra RM, et al. Candidate driver genes in microsatellite-unstable colorectal cancer. International Journal of Cancer. Journal International Du Cancer. 130: 1558-66. PMID 21544814 DOI: 10.1002/Ijc.26167 |
0.327 |
|
| 2012 |
Heinonen M, Ristimäki A. P-0181 Molecular Subtypes of Colorectal Cancer and Their Effect to Clinicopathological Parameters Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)30105-8 |
0.388 |
|
| 2011 |
Thiel A, Mrena J, Ristimäki A. Cyclooxygenase-2 and gastric cancer. Cancer Metastasis Reviews. 30: 387-95. PMID 22002749 DOI: 10.1007/S10555-011-9312-1 |
0.382 |
|
| 2011 |
Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Research : Bcr. 13: R87. PMID 21914172 DOI: 10.1186/Bcr2944 |
0.341 |
|
| 2011 |
Böckelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, Bützow R, Ristimäki A. Prognostic role of CIP2A expression in serous ovarian cancer. British Journal of Cancer. 105: 989-95. PMID 21897396 DOI: 10.1038/Bjc.2011.346 |
0.379 |
|
| 2011 |
Resende C, Thiel A, Machado JC, Ristimäki A. Gastric cancer: basic aspects. Helicobacter. 16: 38-44. PMID 21896084 DOI: 10.1111/J.1523-5378.2011.00879.X |
0.329 |
|
| 2011 |
Böckelman C, Hagström J, Mäkinen LK, Keski-Säntti H, Häyry V, Lundin J, Atula T, Ristimäki A, Haglund C. High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. British Journal of Cancer. 104: 1890-5. PMID 21610708 DOI: 10.1038/Bjc.2011.167 |
0.391 |
|
| 2011 |
Rajecki M, Kangasmäki A, Laasonen L, Escutenaire S, Hakkarainen T, Haukka J, Ristimäki A, Kairemo K, Kangasniemi L, Kiljunen T, Joensuu T, Pesonen S, Hemminki A. Sodium iodide symporter SPECT imaging of a patient treated with oncolytic adenovirus Ad5/3-Δ24-hNIS. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 629-31. PMID 21455206 DOI: 10.1038/Mt.2011.31 |
0.321 |
|
| 2011 |
Niittymäki I, Gylfe A, Laine L, Laakso M, Lehtonen HJ, Kondelin J, Tolvanen J, Nousiainen K, Pouwels J, Järvinen H, Nuorva K, Mecklin JP, Mäkinen M, Ristimäki A, Ørntoft TF, et al. High frequency of TTK mutations in microsatellite-unstable colorectal cancer and evaluation of their effect on spindle assembly checkpoint. Carcinogenesis. 32: 305-11. PMID 21163887 DOI: 10.1093/Carcin/Bgq272 |
0.318 |
|
| 2011 |
Ronkainen H, Vaarala MH, Hirvikoski P, Ristimäki A. HuR expression is a marker of poor prognosis in renal cell carcinoma. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 32: 481-7. PMID 21161467 DOI: 10.1007/S13277-010-0141-6 |
0.386 |
|
| 2011 |
Vento P, Lepistö A, Kärkkäinen P, Ristimäki A, Haglund C, Järvinen HJ. Risk of cancer in patients with chronic pouchitis after restorative proctocolectomy for ulcerative colitis. Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland. 13: 58-66. PMID 19832871 DOI: 10.1111/J.1463-1318.2009.02058.X |
0.304 |
|
| 2011 |
Khanna A, Böckelman C, Schreck I, Weiss C, Visakorpi T, Ristimäki A, Westermarck J. Abstract 4194: Constitutive DNA-damage signaling promotes cancer cell proliferation through Chk1-CIP2A pathway independent of ATM-ATR Cancer Research. 71: 4194-4194. DOI: 10.1158/1538-7445.Am2011-4194 |
0.401 |
|
| 2010 |
Resende C, Ristimäki A, Machado JC. Genetic and epigenetic alteration in gastric carcinogenesis. Helicobacter. 15: 34-9. PMID 21054651 DOI: 10.1111/J.1523-5378.2010.00782.X |
0.313 |
|
| 2010 |
Vaarala MH, Väisänen MR, Ristimäki A. CIP2A expression is increased in prostate cancer. Journal of Experimental & Clinical Cancer Research : Cr. 29: 136. PMID 20964854 DOI: 10.1186/1756-9966-29-136 |
0.338 |
|
| 2010 |
Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, Nokisalmi P, Raki M, Laasonen L, Särkioja M, Rajecki M, Kangasniemi L, Guse K, Helminen A, Ahtiainen L, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Research. 70: 4297-309. PMID 20484030 DOI: 10.1158/0008-5472.Can-09-3567 |
0.345 |
|
| 2010 |
Mrena J, Wiksten JP, Kokkola A, Nordling S, Ristimäki A, Haglund C. COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 31: 1-7. PMID 20237896 DOI: 10.1007/S13277-009-0001-4 |
0.38 |
|
| 2010 |
Guse K, Sloniecka M, Diaconu I, Ottolino-Perry K, Tang N, Ng C, Le Boeuf F, Bell JC, McCart JA, Ristimäki A, Pesonen S, Cerullo V, Hemminki A. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. Journal of Virology. 84: 856-66. PMID 19906926 DOI: 10.1128/Jvi.00692-09 |
0.334 |
|
| 2010 |
Böckelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, Bützow R, Ristimäki A. Abstract 4645: CIP2A is a marker of reduced survival in serous ovarian cancer patients Cancer Research. 70: 4645-4645. DOI: 10.1158/1538-7445.Am10-4645 |
0.403 |
|
| 2009 |
Ghosh M, Aguila HL, Michaud J, Ai Y, Wu MT, Hemmes A, Ristimaki A, Guo C, Furneaux H, Hla T. Essential role of the RNA-binding protein HuR in progenitor cell survival in mice. The Journal of Clinical Investigation. 119: 3530-43. PMID 19884656 DOI: 10.1172/Jci38263 |
0.727 |
|
| 2009 |
Correia M, Machado JC, Ristimäki A. Basic aspects of gastric cancer. Helicobacter. 14: 36-40. PMID 19712166 DOI: 10.1111/J.1523-5378.2009.00696.X |
0.356 |
|
| 2009 |
Koski A, Rajecki M, Guse K, Kanerva A, Ristimäki A, Pesonen S, Escutenaire S, Hemminki A. Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells. The Journal of Gene Medicine. 11: 966-77. PMID 19670332 DOI: 10.1002/Jgm.1373 |
0.335 |
|
| 2009 |
Thiel A, Ganesan A, Mrena J, Junnila S, Nykänen A, Hemmes A, Tai HH, Monni O, Kokkola A, Haglund C, Petrova TV, Ristimäki A. 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4572-80. PMID 19584167 DOI: 10.1158/1078-0432.Ccr-08-2518 |
0.377 |
|
| 2009 |
Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimäki A. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. Journal of the National Cancer Institute. 101: 793-805. PMID 19470954 DOI: 10.1093/Jnci/Djp103 |
0.32 |
|
| 2009 |
Guse K, Diaconu I, Rajecki M, Sloniecka M, Hakkarainen T, Ristimäki A, Kanerva A, Pesonen S, Hemminki A. Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment. Gene Therapy. 16: 1009-20. PMID 19440223 DOI: 10.1038/Gt.2009.56 |
0.354 |
|
| 2009 |
van Hattem WA, Brosens LA, Marks SY, Milne AN, van Eeden S, Iacobuzio-Donahue CA, Ristimäki A, Giardiello FM, Offerhaus GJ. Increased cyclooxygenase-2 expression in juvenile polyposis syndrome. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. 7: 93-7. PMID 19124115 DOI: 10.1016/J.Cgh.2008.07.030 |
0.39 |
|
| 2009 |
Gylfe A, Niittymäki I, Ahonen L, Lehtonen H, Laakso M, Sirkiä J, Nousiainen K, Pouwels J, Järvinen H, Nuorva K, Mecklin J, Ristimäki A, Ørntoft T, Hautaniemi S, Karhu A, et al. Abstract A57: Nonsense‐mediated decay escaping mutations in microsatellite-unstable colorectal cancer Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-A57 |
0.36 |
|
| 2009 |
Khanna A, Böckelman C, Westermarck J, Ristimäki A. 6650 Myc-dependent regulation and prgonostic role of Myc stabilizing protein, CIP2A, in human gastric cancer Ejc Supplements. 7: 403. DOI: 10.1016/S1359-6349(09)71371-0 |
0.326 |
|
| 2008 |
Alberici P, Gaspar C, Franken P, Gorski MM, de Vries I, Scott RJ, Ristimäki A, Aaltonen LA, Fodde R. Smad4 haploinsufficiency: a matter of dosage. Pathogenetics. 1: 2. PMID 19014666 DOI: 10.1186/1755-8417-1-2 |
0.365 |
|
| 2008 |
Kanerva A, Lavilla-Alonso S, Raki M, Kangasniemi L, Bauerschmitz GJ, Takayama K, Ristimäki A, Desmond RA, Hemminki A. Systemic therapy for cervical cancer with potentially regulatable oncolytic adenoviruses. Plos One. 3: e2917. PMID 18698374 DOI: 10.1371/Journal.Pone.0002917 |
0.319 |
|
| 2008 |
Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, Porten M, Herrmann I, Ristimäki A, Virkkunen P, Tarkkanen M, Hakkarainen T, Kanerva A, Rein D, Pesonen S, Hemminki A. Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Research. 68: 5533-9. PMID 18632604 DOI: 10.1158/0008-5472.Can-07-5288 |
0.328 |
|
| 2008 |
Alhopuro P, Phichith D, Tuupanen S, Sammalkorpi H, Nybondas M, Saharinen J, Robinson JP, Yang Z, Chen LQ, Orntoft T, Mecklin JP, Järvinen H, Eng C, Moeslein G, Shibata D, et al. Unregulated smooth-muscle myosin in human intestinal neoplasia. Proceedings of the National Academy of Sciences of the United States of America. 105: 5513-8. PMID 18391202 DOI: 10.1073/Pnas.0801213105 |
0.309 |
|
| 2008 |
Särkioja M, Hakkarainen T, Eriksson M, Ristimäki A, Desmond RA, Kanerva A, Hemminki A. The cyclo-oxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 3'-untranslated region destabilization element can increase specificity. The Journal of Gene Medicine. 10: 744-53. PMID 18338835 DOI: 10.1002/Jgm.1193 |
0.356 |
|
| 2008 |
Visscher DW, Pankratz VS, Santisteban M, Reynolds C, Ristimäki A, Vierkant RA, Lingle WL, Frost MH, Hartmann LC. Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. Journal of the National Cancer Institute. 100: 421-7. PMID 18334709 DOI: 10.1093/Jnci/Djn036 |
0.346 |
|
| 2008 |
Katajisto P, Vaahtomeri K, Ekman N, Ventelä E, Ristimäki A, Bardeesy N, Feil R, DePinho RA, Mäkelä TP. LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis. Nature Genetics. 40: 455-9. PMID 18311138 DOI: 10.1038/Ng.98 |
0.354 |
|
| 2008 |
Eerola H, Heinonen M, Heikkilä P, Kilpivaara O, Tamminen A, Aittomäki K, Blomqvist C, Ristimäki A, Nevanlinna H. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Research : Bcr. 10: R17. PMID 18275599 DOI: 10.1186/Bcr1863 |
0.321 |
|
| 2008 |
Korpi JT, Kervinen V, Mäklin H, Väänänen A, Lahtinen M, Läärä E, Ristimäki A, Thomas G, Ylipalosaari M, Aström P, Lopez-Otin C, Sorsa T, Kantola S, Pirilä E, Salo T. Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. British Journal of Cancer. 98: 766-75. PMID 18253113 DOI: 10.1038/Sj.Bjc.6604239 |
0.307 |
|
| 2008 |
Koljonen V, Böhling T, Haglund C, Ristimäki A. Expression of HuR in Merkel cell carcinoma and in normal skin. Journal of Cutaneous Pathology. 35: 10-4. PMID 18095988 DOI: 10.1111/J.1600-0560.2007.00762.X |
0.31 |
|
| 2008 |
Brosens LA, Keller JJ, Pohjola L, Haglund C, Morsink FH, Iacobuzio-Donahue C, Goggins M, Giardiello FM, Ristimäki A, Offerhaus GJ. Increased expression of cytoplasmic HuR in familial adenomatous polyposis. Cancer Biology & Therapy. 7: 424-7. PMID 18094611 DOI: 10.4161/Cbt.7.3.5417 |
0.414 |
|
| 2008 |
Tommiska J, Bartkova J, Heinonen M, Hautala L, Kilpivaara O, Eerola H, Aittomäki K, Hofstetter B, Lukas J, von Smitten K, Blomqvist C, Ristimäki A, Heikkilä P, Bartek J, Nevanlinna H. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene. 27: 2501-6. PMID 17982490 DOI: 10.1038/Sj.Onc.1210885 |
0.347 |
|
| 2008 |
Khanna A, Böckelman C, Hemmes A, Junttila M, Wiksten JP, Lundin M, Haglund C, Westermarck J, Ristimäki A. CIP2A (Cancerous Inhibitor of Protein Phosphatase 2A) promotes gastric carcinogenesis Ejc Supplements. 6: 200. DOI: 10.1016/S1359-6349(08)71886-X |
0.302 |
|
| 2008 |
Hattem WAv, Brosens L, Ristimäki A, Giardiello FM, Offerhaus J. W1091 Increased Cyclooxygenase-2 Expression in Juvenile Polyposis Syndrome Gastroenterology. 134. DOI: 10.1016/S0016-5085(08)62947-9 |
0.386 |
|
| 2007 |
Heinonen M, Fagerholm R, Aaltonen K, Kilpivaara O, Aittomäki K, Blomqvist C, Heikkilä P, Haglund C, Nevanlinna H, Ristimäki A. Prognostic role of HuR in hereditary breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6959-63. PMID 18056170 DOI: 10.1158/1078-0432.Ccr-07-1432 |
0.401 |
|
| 2007 |
Kajanne R, Leppä S, Luukkainen P, Ustinov J, Thiel A, Ristimäki A, Miettinen PJ. Hydrocortisone and indomethacin negatively modulate EGF-R signaling in human fetal intestine. Pediatric Research. 62: 570-5. PMID 17805209 DOI: 10.1203/Pdr.0B013E318155Ac3B |
0.327 |
|
| 2007 |
Kanerva A, Raki M, Ranki T, Särkioja M, Koponen J, Desmond RA, Helin A, Stenman UH, Isoniemi H, Höckerstedt K, Ristimäki A, Hemminki A. Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity. The Journal of Gene Medicine. 9: 3-9. PMID 17149790 DOI: 10.1002/Jgm.984 |
0.328 |
|
| 2007 |
Ranki T, Kanerva A, Ristimäki A, Hakkarainen T, Särkioja M, Kangasniemi L, Raki M, Laakkonen P, Goodison S, Hemminki A. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. Gene Therapy. 14: 58-67. PMID 16900223 DOI: 10.1038/Sj.Gt.3302830 |
0.338 |
|
| 2006 |
Kohno M, Momoi M, Oo ML, Paik JH, Lee YM, Venkataraman K, Ai Y, Ristimaki AP, Fyrst H, Sano H, Rosenberg D, Saba JD, Proia RL, Hla T. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Molecular and Cellular Biology. 26: 7211-23. PMID 16980623 DOI: 10.1128/Mcb.02341-05 |
0.737 |
|
| 2006 |
Atula T, Hedström J, Ristimäki A, Finne P, Leivo I, Markkanen-Leppänen M, Haglund C. Cyclooxygenase-2 expression in squamous cell carcinoma of the oral cavity and pharynx: association to p53 and clinical outcome. Oncology Reports. 16: 485-90. PMID 16865247 DOI: 10.3892/Or.16.3.485 |
0.392 |
|
| 2006 |
Mrena J, Wiksten JP, Nordling S, Kokkola A, Ristimäki A, Haglund C. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. Journal of Clinical Pathology. 59: 618-23. PMID 16731602 DOI: 10.1136/Jcp.2005.033761 |
0.306 |
|
| 2006 |
Siironen P, Ristimäki A, Narko K, Nordling S, Louhimo J, Andersson S, Haapiainen R, Haglund C. VEGF-C and COX-2 expression in papillary thyroid cancer. Endocrine-Related Cancer. 13: 465-73. PMID 16728574 DOI: 10.1677/Erc.1.01114 |
0.357 |
|
| 2006 |
Mrena J, Wiksten JP, Kokkola A, Nordling S, Haglund C, Ristimäki A. Prognostic significance of cyclin A in gastric cancer. International Journal of Cancer. Journal International Du Cancer. 119: 1897-901. PMID 16708383 DOI: 10.1002/Ijc.21944 |
0.418 |
|
| 2006 |
Milne AN, Carvalho R, Morsink FM, Musler AR, de Leng WW, Ristimäki A, Offerhaus GJ. Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 19: 564-72. PMID 16474375 DOI: 10.1038/Modpathol.3800563 |
0.366 |
|
| 2006 |
Juuti A, Louhimo J, Nordling S, Ristimäki A, Haglund C. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. Journal of Clinical Pathology. 59: 382-6. PMID 16467169 DOI: 10.1136/Jcp.2005.026831 |
0.37 |
|
| 2006 |
Thiel A, Heinonen M, Rintahaka J, Hallikainen T, Hemmes A, Dixon DA, Haglund C, Ristimäki A. Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3beta in gastric cancer cells. The Journal of Biological Chemistry. 281: 4564-9. PMID 16371352 DOI: 10.1074/Jbc.M512722200 |
0.392 |
|
| 2005 |
Mrena J, Wiksten JP, Thiel A, Kokkola A, Pohjola L, Lundin J, Nordling S, Ristimäki A, Haglund C. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7362-8. PMID 16243808 DOI: 10.1158/1078-0432.Ccr-05-0764 |
0.419 |
|
| 2005 |
Sudbø J, Lee JJ, Lippman SM, Mork J, Sagen S, Flatner N, Ristimäki A, Sudbø A, Mao L, Zhou X, Kildal W, Evensen JF, Reith A, Dannenberg AJ. Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. Lancet (London, England). 366: 1359-66. PMID 16226613 DOI: 10.1016/S0140-6736(05)67488-0 |
0.314 |
|
| 2005 |
Erkinheimo TL, Sivula A, Lassus H, Heinonen M, Furneaux H, Haglund C, Butzow R, Ristimäki A. Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma. Gynecologic Oncology. 99: 14-9. PMID 16126263 DOI: 10.1016/J.Ygyno.2005.04.047 |
0.447 |
|
| 2005 |
Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimäki A, von Smitten K, Aittomäki K, Heikkilä P, Blomqvist C, Nevanlinna H. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5098-103. PMID 16033823 DOI: 10.1158/1078-0432.Ccr-05-0173 |
0.351 |
|
| 2005 |
Narko K, Zweifel B, Trifan O, Ristimäki A, Lane TF, Hla T. COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice. Prostaglandins & Other Lipid Mediators. 76: 86-94. PMID 15967164 DOI: 10.1016/J.Prostaglandins.2005.01.002 |
0.742 |
|
| 2005 |
Siironen P, Louhimo J, Nordling S, Ristimäki A, Mäenpää H, Haapiainen R, Haglund C. Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 26: 57-64. PMID 15870511 DOI: 10.1159/000085586 |
0.322 |
|
| 2005 |
Sivula A, Buskens CJ, Van Rees BP, Haglund C, Offerhaus GJA, Van Lanschot JJB, Ristimäki A. Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus International Journal of Cancer. 116: 903-908. PMID 15856454 DOI: 10.1002/Ijc.21134 |
0.385 |
|
| 2005 |
Heinonen M, Bono P, Narko K, Chang SH, Lundin J, Joensuu H, Furneaux H, Hla T, Haglund C, Ristimäki A. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Research. 65: 2157-61. PMID 15781626 DOI: 10.1158/0008-5472.Can-04-3765 |
0.641 |
|
| 2005 |
Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimäki A, Turpeenniemi-Hujanen T. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Research and Treatment. 89: 215-20. PMID 15754118 DOI: 10.1007/S10549-004-0714-4 |
0.354 |
|
| 2005 |
Koljonen V, Lassus P, Tukiainen E, Ristimäki A, Haglund C, Böhling T. Cyclooxygenase-2 expression in primary Merkel cell carcinoma. Journal of Cutaneous Pathology. 32: 55-8. PMID 15660656 DOI: 10.1111/J.0303-6987.2005.00262.X |
0.405 |
|
| 2005 |
Raki M, Kanerva A, Ristimaki A, Desmond RA, Chen DT, Ranki T, Sarkioja M, Kangasniemi L, Hemminki A. 1004. Enhanced Survival Uncovers Liver Toxicity in Mice with Orthotopic Advanced Ovarian Cancer Treated with Gemcitabine and Ad5/3-|[Delta]|24, a Serotype 3 Receptor Targeted Oncolytic Adenovirus Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.551 |
0.333 |
|
| 2004 |
Siironen P, Ristimäki A, Nordling S, Louhimo J, Haapiainen R, Haglund C. Expression of COX-2 is increased with age in papillary thyroid cancer. Histopathology. 44: 490-497. PMID 15139997 DOI: 10.1111/J.1365-2559.2004.01880 |
0.343 |
|
| 2004 |
Erkinheimo TL, Lassus H, Finne P, Van Rees BP, Leminen A, Ylikorkala O, Haglund C, Butzow R, Ristimäki A. Elevated Cyclooxygenase-2 Expression Is Associated with Altered Expression of p53 and SMAD4, Amplification of HER-2/neu, and Poor Outcome in Serous Ovarian Carcinoma Clinical Cancer Research. 10: 538-545. PMID 14760075 DOI: 10.1158/1078-0432.Ccr-0132-03 |
0.381 |
|
| 2004 |
Bizik J, Kankuri E, Ristimäki A, Taieb A, Vapaatalo H, Lubitz W, Vaheri A. Cell–cell contacts trigger programmed necrosis and induce cyclooxygenase-2 expression Cell Death & Differentiation. 11: 183-195. PMID 14555963 DOI: 10.1038/Sj.Cdd.4401317 |
0.341 |
|
| 2004 |
Ristimäki A. Cyclooxygenase 2: from inflammation to carcinogenesis. Novartis Foundation Symposium. 256: 215-226. DOI: 10.1002/0470856734.Ch16 |
0.393 |
|
| 2003 |
Buskens CJ, Ristimäki A, Offerhaus GJA, Richel DJ, Lanschot JJBv. Role of cyclooxygenase-2 in the development and treatment of oesophageal adenocarcinoma. Scandinavian Journal of Gastroenterology. 38: 87-93. PMID 14743889 DOI: 10.1080/00855920310002753 |
0.397 |
|
| 2003 |
Erkinheimo TL, Lassus H, Sivula A, Sengupta S, Furneaux H, Hla T, Haglund C, Butzow R, Ristimäki A. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Research. 63: 7591-4. PMID 14633672 |
0.542 |
|
| 2003 |
Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Van Rees BP, Rio MC, Haglund C, Van Lanschot JJB, Offerhaus GJA, Ristimäki A. Cyclooxygenase-2 and gastric carcinogenesis Apmis. 111: 915-925. PMID 14616542 DOI: 10.1034/J.1600-0463.2003.1111001.X |
0.346 |
|
| 2003 |
Van Rees BP, Sivula A, Thorén S, Yokozaki H, Jakobsson PJ, Offerhaus GJA, Ristimäki A. Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines International Journal of Cancer. 107: 551-556. PMID 14520691 DOI: 10.1002/Ijc.11422 |
0.373 |
|
| 2003 |
Varis A, Van Rees B, Weterman M, Ristimäki A, Offerhaus J, Knuutila S. DNA copy number changes in young gastric cancer patients with special reference to chromosome 19 British Journal of Cancer. 88: 1914-1919. PMID 12799636 DOI: 10.1038/Sj.Bjc.6600969 |
0.303 |
|
| 2003 |
Sudbø J, Ristimäki A, Sondresen JE, Kildal W, Boysen M, Koppang HS, Reith A, Risberg B, Nesland JM, Bryne M. Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions. Oral Oncology. 39: 497-505. PMID 12747975 DOI: 10.1016/S1368-8375(03)00012-5 |
0.366 |
|
| 2003 |
Buskens C, Sivula A, Westerterp M, Offerhaus J, Ristimaki A, Lanschot JV. Adenocarcinomas of the gastro-esophageal junction: A comparative study of the gastric cardia and the esophagus with respect to cyclooxygenase-2 expression Gastroenterology. 124. DOI: 10.1016/S0016-5085(03)80578-4 |
0.314 |
|
| 2002 |
Rossi DJ, Ylikorkala A, Korsisaari N, Salovaara R, Luukko K, Launonen V, Henkemeyer M, Ristimaki A, Aaltonen LA, Makela TP. Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis. Proceedings of the National Academy of Sciences of the United States of America. 99: 12327-32. PMID 12218179 DOI: 10.1073/Pnas.192301399 |
0.355 |
|
| 2001 |
Salmenkivi K, Haglund C, Ristimäki A, Arola J, Heikkilä P. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. The Journal of Clinical Endocrinology and Metabolism. 86: 5615-5619. PMID 11701743 DOI: 10.1210/Jcem.86.11.8052 |
0.373 |
|
| 2001 |
Narko K, Saukkonen K, Ketola I, Bützow R, Heikinheimo M, Ristimäki A. Regulated Expression of Prostaglandin E2 Receptors EP2 and EP4 in Human Ovarian Granulosa-Luteal Cells The Journal of Clinical Endocrinology and Metabolism. 86: 1765-1768. PMID 11297615 DOI: 10.1210/Jcem.86.4.7535 |
0.337 |
|
| 2001 |
Ristimäki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S, Haglund C. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. American Journal of Pathology. 158: 849-853. PMID 11238034 DOI: 10.1016/S0002-9440(10)64033-3 |
0.393 |
|
| 2001 |
Rees BPV, Ristimaki A, Saukkonen K, Morsink FH, Musler AR, Craanen ME, Drillenburg P, Johan G, Offerhaus A. Cyclooxygenase-2 expression during tumor progression and characterization of cox-2 positive stromal cells in the stomach Gastroenterology. 120. DOI: 10.1016/S0016-5085(08)80834-7 |
0.389 |
|
| 2000 |
Ekman N, Arighi E, Rajantie I, Saharinen P, Ristimäki A, Silvennoinen O, Alitalo K. The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner. Oncogene. 19: 4151-8. PMID 10962576 DOI: 10.1038/Sj.Onc.1203763 |
0.308 |
|
| 1998 |
Kosonen O, Kankaanranta H, Malo-Ranta U, Ristimäki A, Moilanen E. Inhibition by nitric oxide-releasing compounds of prostacyclin production in human endothelial cells British Journal of Pharmacology. 125: 247-254. PMID 9786495 DOI: 10.1038/Sj.Bjp.0702042 |
0.301 |
|
| 1997 |
Laitinen M, RistimÄki A, Honkasalo M, Narko K, Paavonen K, Ritvos O. Differential hormonal regulation of vascular endothelial growth factors VEGF, VEGF-B, and VEGF-C messenger ribonucleic acid levels in cultured human granulosa-luteal cells. Endocrinology. 138: 4748-4756. PMID 9348202 DOI: 10.1210/Endo.138.11.5500 |
0.303 |
|
| 1997 |
Narko K, Ritvos O, Ristimäki A. Induction of cyclooxygenase-2 and prostaglandin F2alpha receptor expression by interleukin-1beta in cultured human granulosa-luteal cells. Endocrinology. 138: 3638-3644. PMID 9275047 DOI: 10.1210/Endo.138.9.5388 |
0.344 |
|
| 1997 |
Narko K, Ristimäki A, MacPhee M, Smith E, Haudenschild CC, Hla T. Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression. The Journal of Biological Chemistry. 272: 21455-60. PMID 9261162 DOI: 10.1074/Jbc.272.34.21455 |
0.544 |
|
| 1996 |
Ristimäki A, Narko K, Hla T. Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. The Biochemical Journal. 318: 325-31. PMID 8761489 DOI: 10.1042/Bj3180325 |
0.468 |
|
| 1994 |
Ristimäki A, Garfinkel S, Wessendorf J, Maciag T, Hla T. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. The Journal of Biological Chemistry. 269: 11769-75. PMID 8163473 |
0.623 |
|
| 1994 |
Crofford LJ, Wilder RL, Ristimäki AP, Sano H, Remmers EF, Epps HR, Hla T. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. The Journal of Clinical Investigation. 93: 1095-101. PMID 8132748 DOI: 10.1172/Jci117060 |
0.46 |
|
| 1994 |
Appleby SB, Ristimäki A, Neilson K, Narko K, Hla T. Structure of the human cyclo-oxygenase-2 gene. The Biochemical Journal. 302: 723-7. PMID 7945196 DOI: 10.1042/Bj3020723 |
0.463 |
|
| 1993 |
Hla T, Ristimäki A, Appleby S, Barriocanal JG. Cyclooxygenase gene expression in inflammation and angiogenesis. Annals of the New York Academy of Sciences. 696: 197-204. PMID 7509130 DOI: 10.1111/J.1749-6632.1993.Tb17152.X |
0.471 |
|
| 1988 |
Renkonen R, Ristimaki A, Hayry P. Interferon-gamma protects human endothelial cells from lymphokine-activated killer cell-mediated lysis European Journal of Immunology. 18: 1839-1842. PMID 3144455 DOI: 10.1002/Eji.1830181129 |
0.318 |
|
| Show low-probability matches. |